Bethanechol transmucosal - Acacia Pharma

Drug Profile

Bethanechol transmucosal - Acacia Pharma

Alternative Names: APD 515

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acacia Pharma
  • Class Neuroprotectants; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Xerostomia

Most Recent Events

  • 20 Aug 2015 Phase-II development is ongoing for Xerostomia in Europe
  • 15 Oct 2013 Final Efficacy and Adverse events data from a proof-of-concept phase II trial in Xerostomia (in patients with advanced cancer) released by Acacia Pharma
  • 03 Sep 2013 Acacia Pharma secures loan (£15 million) from Fidelity Biosciences and Novo A/S to finance development of APD 515 for Xerostomia, as well as amisulpride (as APD 421 and APD 403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top